CL2014001639A1 - Uso simultaneo, separado o secuencial de un agonista de ppar gamma seleccionado del grupo de glitazonas con un activador de nrf2 aislado seleccionado de un grupo especifico o una composicion que lo comprende, para el tratamiento de un trastorno autoinmune y/o inflamatorio; composicion farmaceutica que comprende a dicho agonista de ppar gamma y al activador de nrf2; y kit que la comprende. - Google Patents

Uso simultaneo, separado o secuencial de un agonista de ppar gamma seleccionado del grupo de glitazonas con un activador de nrf2 aislado seleccionado de un grupo especifico o una composicion que lo comprende, para el tratamiento de un trastorno autoinmune y/o inflamatorio; composicion farmaceutica que comprende a dicho agonista de ppar gamma y al activador de nrf2; y kit que la comprende.

Info

Publication number
CL2014001639A1
CL2014001639A1 CL2014001639A CL2014001639A CL2014001639A1 CL 2014001639 A1 CL2014001639 A1 CL 2014001639A1 CL 2014001639 A CL2014001639 A CL 2014001639A CL 2014001639 A CL2014001639 A CL 2014001639A CL 2014001639 A1 CL2014001639 A1 CL 2014001639A1
Authority
CL
Chile
Prior art keywords
ppar gamma
gamma agonist
nrf2 activator
group
composition
Prior art date
Application number
CL2014001639A
Other languages
English (en)
Spanish (es)
Inventor
Bjoern Colin Kahrs
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48610741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001639(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of CL2014001639A1 publication Critical patent/CL2014001639A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2014001639A 2011-12-19 2014-06-19 Uso simultaneo, separado o secuencial de un agonista de ppar gamma seleccionado del grupo de glitazonas con un activador de nrf2 aislado seleccionado de un grupo especifico o una composicion que lo comprende, para el tratamiento de un trastorno autoinmune y/o inflamatorio; composicion farmaceutica que comprende a dicho agonista de ppar gamma y al activador de nrf2; y kit que la comprende. CL2014001639A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11194292 2011-12-19
EP12004652 2012-06-21
US201261663761P 2012-06-25 2012-06-25

Publications (1)

Publication Number Publication Date
CL2014001639A1 true CL2014001639A1 (es) 2014-11-14

Family

ID=48610741

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001639A CL2014001639A1 (es) 2011-12-19 2014-06-19 Uso simultaneo, separado o secuencial de un agonista de ppar gamma seleccionado del grupo de glitazonas con un activador de nrf2 aislado seleccionado de un grupo especifico o una composicion que lo comprende, para el tratamiento de un trastorno autoinmune y/o inflamatorio; composicion farmaceutica que comprende a dicho agonista de ppar gamma y al activador de nrf2; y kit que la comprende.

Country Status (18)

Country Link
US (6) US20130158077A1 (enExample)
EP (1) EP2793876B1 (enExample)
JP (1) JP6132850B2 (enExample)
KR (2) KR102188487B1 (enExample)
CN (1) CN103998035B (enExample)
AR (1) AR089301A1 (enExample)
AU (4) AU2012358420B9 (enExample)
BR (1) BR112014014809A8 (enExample)
CA (1) CA2859635C (enExample)
CL (1) CL2014001639A1 (enExample)
EA (1) EA201400729A1 (enExample)
ES (1) ES2959111T3 (enExample)
HK (1) HK1200711A1 (enExample)
IL (1) IL233134A0 (enExample)
MX (2) MX394473B (enExample)
PH (1) PH12014501029A1 (enExample)
SG (1) SG11201403241XA (enExample)
WO (1) WO2013092269A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2554347C2 (ru) 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
MX339243B (es) 2011-02-03 2016-05-18 Vtv Therapeutics Llc Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos.
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
MX2015007479A (es) * 2012-12-11 2015-09-04 Metabolic Solutions Dev Co Llc Tiazolidindionas ahorradoras de receptores activados proliferadores de peroxisoma (ppar) y combinaciones para el tratamiento de enfermedades neurodegenerativas.
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
UA116648C2 (uk) 2013-03-14 2018-04-25 Алкермес Фарма Айерленд Лімітед Фумарати як проліки та їх застосування при лікуванні різних захворювань
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
WO2015035184A1 (en) 2013-09-06 2015-03-12 Xenoport, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016071727A1 (en) 2014-11-04 2016-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
WO2016074684A1 (en) * 2014-11-11 2016-05-19 Syddansk Universitet Fumaric acid derivatives for medical use
MA40990A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
KR101704410B1 (ko) 2015-07-22 2017-02-22 대구가톨릭대학교산학협력단 사파논 a를 함유하는 심혈관질환의 예방 및 치료용 조성물
WO2017072699A1 (en) * 2015-10-28 2017-05-04 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
CN108699011B (zh) * 2016-02-03 2022-05-06 参宿七制药股份有限公司 Nrf2活化性化合物及其用途
CN106389457A (zh) * 2016-11-30 2017-02-15 胡立志 PPAR‑γ激动剂在制备治疗脱发药物中的应用及治疗脱发的药物
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN108685903B (zh) * 2018-07-05 2019-10-18 陕西师范大学 鼠尾草酚在制备防治实验性自身免疫性脑脊髓炎药物的应用
WO2020094767A1 (en) 2018-11-08 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of nrf2 activators for the treatment of staphylococcus aureus infections
KR20210096162A (ko) * 2018-11-27 2021-08-04 쿄와 기린 가부시키가이샤 의약 조성물
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
CN111606828B (zh) * 2019-02-22 2023-07-28 浙江海正药业股份有限公司 (E)-α,β-不饱和酰胺化合物的晶型及其制备方法和用途
CN109846867A (zh) * 2019-03-29 2019-06-07 北京中医药大学 花姜酮用于制备抗心肌缺血的药物的用途
WO2021024054A1 (en) * 2019-08-05 2021-02-11 International Business Machines Corporation Combination therapy to achieve enhanced antimicrobial activity
CN110279866B (zh) * 2019-08-12 2021-06-29 浙江养生堂天然药物研究所有限公司 包含柠檬苦素类化合物和噻唑烷二酮类药物的组合产品
CN110613712B (zh) * 2019-10-22 2021-06-29 上海交通大学医学院附属第九人民医院 中药组合物及其在治疗血管炎症和内皮损伤中的应用
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
CN113244221B (zh) * 2020-02-12 2022-10-25 华东师范大学 双甲基鼠尾草酚在制备治疗恶病质疾病的药物中的应用
US20250002436A1 (en) * 2020-02-24 2025-01-02 Robert F. Hofmann Naphthoquinone-based chalcone derivatives and uses thereof
US20230134760A1 (en) * 2020-03-04 2023-05-04 Hongbing Wang Car and nrf2 dual activator agents for cyclophosphamide-based and doxorubicin-based treatments of cancer
EP4117785A4 (en) * 2020-03-13 2024-04-17 Marc J. Simard METHODS OF TREATMENT OF MULTIPLE SCLEROSIS
CN111574437A (zh) * 2020-06-22 2020-08-25 上海长车生物科技有限公司 (e)-3-芳杂环基丙-2-烯酸衍生物及其制备和用途
CN111529514A (zh) * 2020-06-23 2020-08-14 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种特丁基对苯二酚的应用及治疗椎间盘退变的药物
WO2022056439A1 (en) * 2020-09-14 2022-03-17 Triterpenoid Therapeutics, Inc. Analogs of cddo-2p-im and cddo-3p-im
US20250134845A1 (en) * 2022-02-15 2025-05-01 Emory University Fumaric Acid Esters, Inhalation Administration Methods, Pharmaceutical Uses and Compositions
KR20230123323A (ko) 2022-02-16 2023-08-23 대구대학교 산학협력단 알릴 이소티오시아네이트(Allyl isothiocyanate)를 유효성분으로 포함하는 골 대사성 질환의 예방, 개선 또는 치료용 조성물
CN114414809B (zh) * 2022-03-28 2022-06-21 中元伯瑞生物科技(珠海横琴)有限公司 用于诊断尘肺病的生物标志物的应用
WO2024047248A1 (en) 2022-09-02 2024-03-07 Institut National de la Santé et de la Recherche Médicale Use of nrf2 activators for the treatment of cerebral small vessel disease
CN117137897B (zh) * 2023-10-31 2024-02-13 中国中医科学院中药研究所 索法酮在制备用于预防/治疗银屑病的药物中的应用

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US807113A (en) 1905-03-27 1905-12-12 Frederick O Dyer Puzzle.
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0306228B1 (en) 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
ES2317688T3 (es) 1998-01-29 2009-04-16 Amgen Inc. Moduladores ppar-gamma.
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
DK1192137T3 (da) 1999-06-30 2013-11-11 Amgen Inc Forbindelser til modulering af PPAR-gamma aktivitet
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
US6403121B1 (en) 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
US20040013643A1 (en) 2000-09-19 2004-01-22 Novlmmune S.A. Methods for treatment of multiple sclerosis with statins
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
AU2002219236B2 (en) 2001-01-12 2006-02-09 Biogen International Gmbh Fumaric acid amides
DE10101307A1 (de) 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
GB2373725A (en) 2001-03-30 2002-10-02 Novartis Ag Use of a PPAR gamma agonist in the production of a medicament for the prevention or treatment of diseases associated with IL-10 production
CA2440017A1 (en) * 2001-05-03 2002-11-14 Cornell Research Foundation, Inc. Treatment of hpv caused diseases
FR2825023B1 (fr) 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
BRPI0407074A (pt) 2003-01-29 2006-01-24 Takeda Pharmaceutical Método para produção de uma preparação revestida, preparação revestida, e, método para melhorar a dissolução do cloridreto de pioglitazona de uma preparação revestida com cloridreto de pioglitazona
WO2004098510A2 (en) * 2003-04-30 2004-11-18 Beth Israel Deaconess Medical Center Cystic fibrosis therapy
ATE380027T1 (de) 2003-09-09 2007-12-15 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
DE10342423A1 (de) 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
EP1691806A2 (en) 2003-12-03 2006-08-23 Smithkline Beecham Corporation Novel therapeutic method and compositions
AU2005221140A1 (en) 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of PPAR (gamma) activity
AU2005259864A1 (en) 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
ITMI20041825A1 (it) 2004-09-24 2004-12-24 Medestea Res & Production Srl Agonisti dei ricettori attivanti la proliferazione dei perossisomi, utili nella prevenzione o nel trattamento della gastrite
DE14172396T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US20080004344A1 (en) 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
GB0504206D0 (en) 2005-03-01 2005-04-06 Glaxo Group Ltd Combination therapy
DE102005022845A1 (de) 2005-05-18 2006-11-23 Fumapharm Ag Thiobernsteinsäurederivate und deren Verwendung
DE602006011910D1 (de) 2005-07-07 2010-03-11 Aditech Pharma Ag Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
EP1951206A1 (en) 2005-10-07 2008-08-06 Aditech Pharma AB Controlled release pharmaceutical compositions comprising a fumaric acid ester
WO2007042035A2 (en) 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
HRP20160679T1 (hr) 2005-12-22 2016-07-15 Takeda Pharmaceutical Company Limited Kruti pripravak koji sadrži senzibilizator inzulina
AU2007248473B2 (en) 2006-05-05 2011-01-27 The Regents Of The University Of Michigan Bivalent Smac mimetics and the uses thereof
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
CA2663347A1 (en) 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
WO2008096271A2 (en) 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
PT2137537E (pt) 2007-02-08 2013-08-22 Biogen Idec Inc Composições e respectivas utilizações para o tratamento da esclerose múltipla
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US20100184783A1 (en) 2007-07-11 2010-07-22 Johan Raud Combination for use in the treatment of inflammatory atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
LT2252283T (lt) * 2008-01-11 2019-03-25 Reata Pharmaceuticals, Inc. Sintetiniai triterpenoidai ir jų panaudojimo būdai gydant ligą
WO2009097997A1 (de) 2008-02-07 2009-08-13 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
DE102008030023A1 (de) 2008-06-16 2009-12-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung einer durch Parasiten verursachten Krankheit
GB0913672D0 (en) 2009-08-05 2009-09-16 Argenta Discovery Ltd Glitazones
RU2554347C2 (ru) 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
US20110190242A1 (en) * 2008-09-23 2011-08-04 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
US20100087481A1 (en) 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
ES2646816T3 (es) 2009-02-13 2017-12-18 Reata Pharmaceuticals, Inc. Composiciones de dosificaciones orales de liberación retardada que contienen CDDO-Me amorfo
NZ617130A (en) 2009-04-29 2015-06-26 Biogen Ma Inc Treatment of neurodegeneration and neuroinflammation
WO2011039175A1 (en) * 2009-09-29 2011-04-07 Bodo Melnik Treatment of acne vulgaris, rosacea and androgenetic alopecia and cancer protection in smokers, obesity and diabetes mellitus
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia
NZ600421A (en) 2009-12-15 2014-06-27 Metabolic Solutions Dev Co Llc Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
ME02317B (me) 2010-02-12 2016-06-20 Biogen Ma Inc Neuroprotekcija kod demijelinizacijskih bolesti
US8486922B2 (en) * 2010-04-28 2013-07-16 Chien-Hung Chen Composition
MX390695B (es) 2010-09-21 2025-03-21 Intekrin Therapeutics Inc Composiciones farmaceuticas solidas antidiabeticas
US20140080795A1 (en) 2010-11-19 2014-03-20 University Of Rochester NRF2 Deficiency Influences Susceptibility to Steroid Resistance via HDAC2 Reduction
CN102552140B (zh) * 2011-01-12 2013-05-29 北京人福军威医药技术开发有限公司 罗格列酮的液体组合物
CA2865316A1 (en) 2011-04-28 2012-11-01 Gino Cortopassi Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
US20140308244A1 (en) 2011-08-08 2014-10-16 The Board Of Trustees Of The Leland Stanford Junior University Combination Therapy for Treatment of Inflammatory Demyelinating Disease
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US8865747B2 (en) 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
ME02926B (me) 2012-04-27 2018-04-20 Reata Pharmaceuticals Inc 2,2-difluoropropionamidni derivati bardoksolon metila, polimorfni oblici i postupci za njihovu upotrebu
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
EA201792096A3 (ru) 2013-01-30 2018-05-31 Интекрин Терапьютикс, Инк. РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
EA201592020A1 (ru) 2013-04-22 2016-05-31 Кадила Хелзкэр Лимитед Новая композиция для неалкогольной жировой болезни печени (нажбп)
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
DK3388064T3 (da) 2014-04-02 2021-04-19 Minoryx Therapeutics S L 2,4-thiazolidindionderivater i behandling af forstyrrelse i centralnervesystemet
WO2016074684A1 (en) 2014-11-11 2016-05-19 Syddansk Universitet Fumaric acid derivatives for medical use
AU2017326261A1 (en) 2016-09-13 2019-04-04 Intekrin Therapeutics, Inc. Treatment of multiple sclerosis with CHS-131
US11382889B2 (en) 2018-04-19 2022-07-12 Institut D'investigació Biomèdica De Bellvitge (Idibell) NRF2 activators for the prevention and/or treatment of axonal degeneration
US20210228558A1 (en) 2018-06-06 2021-07-29 Minoryx Therapeutics S.L. Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
KR20210031435A (ko) 2018-06-06 2021-03-19 미노릭스 테라퓨틱스 에스.엘. 치료학적 유효량의 5-[[4-[2-[5-(1-히드록시에틸)피리딘-2-일]에톡시]페닐]메틸]-1,3-티아졸리딘-2,4-디온을 투여하는 방법
SI3801515T1 (sl) 2018-06-06 2025-07-31 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion in soli za uporabo pri zdravljenju mitohondrijske bolezni

Also Published As

Publication number Publication date
AU2021201390B2 (en) 2023-02-09
EA201400729A1 (ru) 2014-12-30
AU2012358420B2 (en) 2017-06-15
AU2012358420A1 (en) 2014-07-31
KR20220139414A (ko) 2022-10-14
US12083107B2 (en) 2024-09-10
US20170065571A1 (en) 2017-03-09
CA2859635A1 (en) 2013-06-27
SG11201403241XA (en) 2014-07-30
ES2959111T3 (es) 2024-02-20
AU2017225019B2 (en) 2019-04-11
US20240423967A1 (en) 2024-12-26
KR102188487B1 (ko) 2020-12-09
AU2017225019A1 (en) 2017-09-28
US20230190720A1 (en) 2023-06-22
JP6132850B2 (ja) 2017-05-24
CN103998035B (zh) 2017-10-24
AU2021201390A1 (en) 2021-03-18
EP2793876B1 (en) 2023-10-04
US20130172391A1 (en) 2013-07-04
CN103998035A (zh) 2014-08-20
HK1200711A1 (en) 2015-08-14
JP2015504871A (ja) 2015-02-16
KR20140113689A (ko) 2014-09-24
BR112014014809A2 (pt) 2017-06-13
US10426763B2 (en) 2019-10-01
WO2013092269A1 (en) 2013-06-27
US20190381023A1 (en) 2019-12-19
MX2014007254A (es) 2014-08-01
PH12014501029A1 (en) 2014-06-23
CA2859635C (en) 2022-06-21
EP2793876C0 (en) 2023-10-04
AU2019204493B2 (en) 2020-12-03
AR089301A1 (es) 2014-08-13
AU2012358420B9 (en) 2017-06-29
US20130158077A1 (en) 2013-06-20
US11484530B2 (en) 2022-11-01
IL233134A0 (en) 2014-07-31
MX394473B (es) 2025-03-24
AU2019204493A1 (en) 2019-07-11
EP2793876A1 (en) 2014-10-29
BR112014014809A8 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
CL2014001639A1 (es) Uso simultaneo, separado o secuencial de un agonista de ppar gamma seleccionado del grupo de glitazonas con un activador de nrf2 aislado seleccionado de un grupo especifico o una composicion que lo comprende, para el tratamiento de un trastorno autoinmune y/o inflamatorio; composicion farmaceutica que comprende a dicho agonista de ppar gamma y al activador de nrf2; y kit que la comprende.
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CO2019003182A2 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
DK3142750T3 (da) Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
DK3267984T3 (da) Forbindelserne 1,2,4-oxadiazol og thoadiazol som immunmodulatorer
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2014003462A1 (es) Uso de compuestos aminotriazolopiridinas sustituidos, en el tratamiento de afecciones inflamatorias, autoinmunitarias, proliferativas, alergias, rechazo de trasplantes, entre otras; composicion farmaceutica que los comprende; combinacion farmaceutica.
BR112016030787A2 (pt) entidade química, composição farmacêutica e seu uso
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
ECSP11011417A (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
ES2897914T8 (es) Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos
BR112017020358A2 (pt) composição farmacêutica de tetraciclina para uso dermatológico
DK3150578T3 (da) Ny pyrrolidinforbindelse og anvendelse som melanocortin-receptoragonist
CL2014003339A1 (es) Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2016001266A1 (es) Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo.
MX373268B (es) Compuestos ppar para uso en el tratamiento de enfermedades fibroticas.